On March 24, 2026, Spectral AI, Inc. (Nasdaq: MDAI) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a research and development revenue of $19.7 million for the full year, with Q4 revenue at $3.8 million. The cash balance improved significantly to $15.4 million at year-end, up from $5.2 million in the previous year. CEO Vincent Capone highlighted the pivotal year for the company, marked by the submission of their De Novo 510(k) application to the FDA for their DeepView System, aimed at enhancing medical diagnostics in wound care. The company also received $31.7 million in funding from BARDA to support further development of the DeepView System. Looking ahead, Spectral AI forecasts revenue of approximately $18.5 million for 2026, primarily driven by ongoing development efforts. The company will host a conference call to discuss these results and future strategies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.